Literature DB >> 21716157

Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.

W Glenn McCluggage1.   

Abstract

Ovarian carcinomas comprise a heterogeneous group of neoplasms, the four most common subtypes being serous, endometrioid, clear cell and mucinous. In recent years, our understanding of the underlying pathogenesis and initiating molecular events in the different tumour subtypes has greatly increased, and although ovarian carcinoma is often considered clinically as one disease, there is now a much greater realisation that the various subtypes have a different natural behaviour and prognosis. At present, adjuvant therapy is mainly dependent upon tumour stage and grade rather than type; however, this is likely to change in the future with the development of new chemotherapeutic agents and targeted therapies and clinical trials are necessary to evaluate the efficacy of different agents in clear cell, mucinous and low grade serous carcinomas, neoplasms which are considered relatively resistant to traditional chemotherapeutic regimes. In this review, the major subtypes of ovarian carcinoma are discussed. It is now firmly established that there are two distinct types of ovarian serous carcinoma, low grade and high grade, the former being much less common and arising in many cases from a serous borderline tumour. Low grade and high grade serous carcinoma represent two distinct tumour types with a different underlying pathogenesis rather than low grade and high grade variants of the same neoplasm. Both are usually advanced stage (stage III or IV) at diagnosis. B-raf and k-ras mutations are important molecular events in low grade serous carcinomas while high grade serous carcinomas are almost always associated with TP53 mutation. There is now emerging and compelling evidence that many high grade serous carcinomas (by far the most common subtype of ovarian carcinoma) actually arise from the epithelium of the distal fallopian tube. Future studies regarding the initiating molecular events in the development of this aggressive neoplasm should concentrate on this site. Primary ovarian mucinous carcinomas are uncommon, almost always unilateral and stage I, and largely of so-called intestinal or enteric type. Most arise in a stepwise manner from a pre-existing mucinous cystadenoma and mucinous borderline tumour. Endometrioid and clear cell carcinomas typically present as low stage neoplasms and in many, or most, cases arise from endometriosis; the former are usually well differentiated and there is now evidence that the majority of neoplasms reported in the past as high grade endometrioid carcinoma are of serous type. WT1 is useful in this regard since it is a relatively specific marker of a serous phenotype. It is recommended that different subtypes of ovarian carcinoma are graded using different systems rather than employing a universal grading system.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21716157     DOI: 10.1097/PAT.0b013e328348a6e7

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  136 in total

1.  NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.

Authors:  Alan P Venook; Maria E Arcila; Al B Benson; Donald A Berry; David Ross Camidge; Robert W Carlson; Toni K Choueiri; Valerie Guild; Gregory P Kalemkerian; Razelle Kurzrock; Christine M Lovly; Amy E McKee; Robert J Morgan; Anthony J Olszanski; Mary W Redman; Vered Stearns; Joan McClure; Marian L Birkeland
Journal:  J Natl Compr Canc Netw       Date:  2014-11       Impact factor: 11.908

Review 2.  Epithelial ovarian cancer - more data, more questions?

Authors:  Stefanie Aust; Dietmar Pils
Journal:  Wien Med Wochenschr       Date:  2014-11-13

3.  Clear Cell Adenocarcinofibroma Ovary - A Rare Histopathological Variant with Unusual Presentation.

Authors:  Manjit Kaur; Navtej Singh; Amrit Pal Singh Rana
Journal:  J Clin Diagn Res       Date:  2016-05-01

4.  Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target.

Authors:  Alfredo Perales-Puchalt; Nikolaos Svoronos; Melanie R Rutkowski; Michael J Allegrezza; Amelia J Tesone; Kyle K Payne; Jayamanna Wickramasinghe; Jenny M Nguyen; Shane W O'Brien; Kiranmai Gumireddy; Qihong Huang; Mark G Cadungog; Denise C Connolly; Julia Tchou; Tyler J Curiel; Jose R Conejo-Garcia
Journal:  Clin Cancer Res       Date:  2016-07-19       Impact factor: 12.531

5.  Three-dimensional culture and clinical drug responses of a highly metastatic human ovarian cancer HO-8910PM cells in nanofibrous microenvironments of three hydrogel biomaterials.

Authors:  Hong Song; Guo-Hui Cai; Jian Liang; Di-Shu Ao; Huan Wang; Ze-Hong Yang
Journal:  J Nanobiotechnology       Date:  2020-06-11       Impact factor: 10.435

Review 6.  [Histological grading of epithelial ovarian cancer. Review and recommendation].

Authors:  S Hauptmann; A du Bois; I Meinhold-Herlein; J Pfisterer; S Avril
Journal:  Pathologe       Date:  2014-09       Impact factor: 1.011

7.  CT texture analysis in histological classification of epithelial ovarian carcinoma.

Authors:  He An; Yiang Wang; Esther M F Wong; Shanshan Lyu; Lujun Han; Jose A U Perucho; Peng Cao; Elaine Y P Lee
Journal:  Eur Radiol       Date:  2021-01-06       Impact factor: 5.315

8.  Cullin-1 promotes cell proliferation via cell cycle regulation and is a novel in prostate cancer.

Authors:  Haowen Jiang; Donghua He; Hua Xu; Jun Liu; Lianxi Qu; Shijun Tong
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

Review 9.  The role of the fallopian tube in the origin of ovarian cancer.

Authors:  Britt K Erickson; Michael G Conner; Charles N Landen
Journal:  Am J Obstet Gynecol       Date:  2013-04-10       Impact factor: 8.661

Review 10.  Secondary and tertiary ovarian cancer recurrence: what is the best management?

Authors:  Simone Garzon; Antonio Simone Laganà; Jvan Casarin; Ricciarda Raffaelli; Antonella Cromi; Massimo Franchi; Fabio Barra; Ibrahim Alkatout; Simone Ferrero; Fabio Ghezzi
Journal:  Gland Surg       Date:  2020-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.